The ending of certain subsidies could result in increased premiums for Medicare Part D drug coverage next year, affecting millions. This change comes as government support for insurers is set to conclude.
The Inflation Reduction Act of 2022 capped Medicare patients’ drug spending at $2,000 starting in 2025. This policy altered how insurers pay for medications, initially leaving them uncertain about premium costs. To assist insurers during this transition, the Biden administration provided temporary subsidies.
The subsidies, expected to run through 2027, will now end a year earlier. Dr. Mehmet Oz, overseeing Medicare and Medicaid services, announced the change, criticizing prior financial aid to insurers. The Government Accountability Office estimated subsidy costs at $9.8 billion for 2025 and 2026, with about 23 million enrolled in Medicare Part D standalone plans during that period.
Oz argued that subsidies aren’t needed anymore, suggesting a modest increase of under $10 for most Medicare users next year. Juliette Cubanski from the Program on Medicare Policy at KFF indicated, however, potential higher costs. She highlighted that current subsidies trim average drug plan premiums by $16, preventing nearly a 50% increase in absence of aid.
Stacie Dusetzina, a health policy professor at Vanderbilt University, expressed concern on subsidy termination, stressing its impact on traditional Medicare. The end differs in effect across plans, with Medicare Advantage having greater premium flexibility.
Dusetzina mentioned that reduced subsidies might encourage a shift from traditional Medicare to Medicare Advantage, known for lower premiums but limited provider options. Such movements demand careful planning for long-term health needs.
Leave a Reply